Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Infinity regains worldwide rights for hedgehog pathway inhibitor program

Nov. 16, 2007

Enrollment begins for RH1 study in solid tumors or non-Hodgkin's lymphoma

Nov. 15, 2007

Synta initiates SYMMETRY phase III clinical trial of elesclomol in metastatic melanoma

Nov. 15, 2007

First marketing authorization application submitted for Advexin

Nov. 14, 2007

Expression Genetics receives grant from the National Cancer Institute to develop EGEN-001

Nov. 14, 2007

Antisense initiates collaborative research program to examine ATL-1101 for prostate cancer

Nov. 14, 2007

Docetaxel/telatinib combination shows promise in cancer patients

Nov. 14, 2007

VioQuest cancer agents progress through early studies

Nov. 14, 2007

AVEO reports positive results from phase I clinical trial of AV-951

Nov. 13, 2007

Synta initiates phase I clinical study of novel Hsp90 inhibitor STA-9090

Nov. 13, 2007

Popular Stories

Today's news in brief
BioWorld
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
VST Bio’s VB-001 is neuroprotector after stroke
BioWorld Science
At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...